Multiple sclerosis market to generate sales of $29.8 bn by 2030: GlobalData
Tolebrutinib is expected to be the leading BTK inhibitor by 2030, with forecasted sales of approximately $2.6B across the 7MM
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ocrevus
US FDA approves TG Therapeutics’ multiple sclerosis drug
The approval by the US Food and Drug Administration (USFDA) widens the number of such drugs available for treating the disorder to…
New data for Roche’s Ocrevus show benefit in disability progression and cognitive decline in…
The treatment with Ocrevus resulted in a majority of patients experiencing no disease progression in a one-year analysis of…
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive…
Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional…
FDA approves Biogen and Alkermes’ multiple sclerosis drug
The approval is good news for Biogen as its top-selling drug Tecfidera, also a multiple sclerosis treatment, is facing patent…